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cell therapy in atrophied muscles in SCI patients.
Setting: Out Patient Treatment, Universidad Maimonides, Buenos Aires, Argentina.
Methods: After receiving spinal cord cell therapy and intensive rehabilitation, 7 chronic
complete spinal cord injury (SCI) patients (4 people with paraplegia and 3 people
with quadriplegia) regained muscular electrical activity in previously denervated
territories. However, signs of severe muscular atrophy persisted. Looking to reverse
chronic muscular atrophy, atrophied muscles with electrical activity were implanted
with autologous type 1 macrophages (Mo1) and autologous tissue-specific T helper 1
Cells (Th1) associated with autologous muscular progenitor cells (MPC). The Mo1
and Th1 used cells were named Effector Cells (EC). Each muscle received between
6 to 8 implants, one every 6 weeks. Cellular therapy was combined with intensive
rehabilitation program.
Results: Sonogram and histological signs of recovery started eight weeks after the first
implant. Sonograms showed progressively muscle volume increasing and gradually
replacement of hyperechogenic muscle tissue by hypoechogenic muscle bands
(resembling normal muscular structure). New bands were distributed parallel to
the main muscle axis, along the entire muscular length. Histological samples of
hypoechogenic bands showed new and normal muscular tissue. Changes were
seen in 7/7 patients. Non-significant side events were detected in any patient over
the 24 months of follow up.
Conclusions: The results presented here suggest that the combination of immune
and regenerative cell therapy may play an important therapeutic role in clinical and
histological recovery of chronic muscular atrophy.

1

Introduction

In the last 15 years, our group has worked on cell
therapy protocols to regenerate connections between
both segments of a spinal cord in chronic complete
SCI patients [1, 2]. One of the main problems that this
cellular program approached was the existence of a
scar tissue at the site of the spinal cord lesion. Similar
to what happens with the fibrotic muscle, collagen

types 1 and 3 present at the scar place, are the major
obstacles for the spinal cord pathways to reconnect
both ends [3, 4]. Axons and dendrites, as well as new
interconnecting neurons, cannot growth on this type of
fibrotic extracellular matrix. To overcome this problem, we based on the fact set by several authors [5, 6]
what have postulated that Mo1 and Th1 environment
promote backward differentiation of myofibroblasts
into normal fibroblasts as well as favor glia and
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Abbreviations
SCI: spinal cord injury
Mo1: type 1 macrophages
Th1: T helper 1 cells.
MPC: muscular progenitor cells
EC: effector cells
NPC : neural progenitor cells
IHC : immunohistochemistry
MNC: mononuclear cells

neuronal development. Following these concepts, as
well as previous findings [1, 2, 7] it was postulated
that the use of autologous effector cells (EC) against
central nervous tissue antigens, associated with autologous neural progenitor cells (NPC), might promote
neural fiber, glia and interconnecting neuron regeneration and revert the quality of the scar tissue. Therefore,
the treatment could induce the reconnection between
both segments of the injured spinal cord. To prove
the feasibility of this combined cellular approach for
complete chronic SCI patient, a phase I and II trial
was conducted between 2013 and 2015. As a result of
this treatment, previously denervated muscles showed
signs of electrical activity associated with the patients’
voluntary intention of muscle movement [7].
Although the electromyographic record suggested
re-innervation and the patients continued the rehabilitation, very little signs of muscular trophism recovery
were observed. Histological examination of compromised muscles showed severe sings of muscular
atrophy with fibrous and fat infiltration (Fig. 1).
Immunohistochemistry (IHC) revealed the presence
of some neuromuscular plaques on the atrophic
muscle fibers, coincident with the electromyographic
signs. Muscular progenitor cells from the interstitium,
rather than from the satellite cells [7, 8], did not appear
to integrate with the pre-existing muscle fibers and
the endomysium matrix was rich in collagen type I
fibers.
Because the combined therapy of EC with NPC
seemed to overcome the obstacle of the spinal cord
chronic scar tissue allowing the reconnection between
the two spinal cord ends, and because it was not
enough the muscular electrical activity restoration to
improve the muscular trophism conditions, our group

DMEM: Dulbecco's Modified Eagle Medium
DMSO: dimethyl sulfoxide
FACS: fluorescence-activated cell sorting
aMSC: adipose mesenchymal stem cells
ISCT: International Society for Cellular Therapy
GMP: good manufacturing practices
AFO: ankle foot orthosis

Fig. 1 Quadriceps evaluation patient #7: (A, B) needle electromyography activity in a flaccid muscle without muscular contraction;
(C) ultrasound that shows signs of severe atrophy (*) transversal
measure of the muscle 1.1 cm of thickness is observed; (D) muscle
biopsy with signs of severe muscular atrophy, fat infiltration and
fibrosis.

decided to implant locally in the affected muscles
autologous, tissue-specific EC against skeletal muscle,
associated to autologous MPC [9]
We postulated the hypothesis that the implanted
cells could reverse the endomysium fibrosis to proregenerative extracellular matrix (ECM) allowing the
recovery of the re-innervated atrophied muscle fibers,
making them functional effective.
The present paper describes signs of efficacy
based on clinical, sonogram and histological changes
observed on 7 chronic complete SCI patients.

2
2.1

Methods
EC Preparation

Autologous mononuclear cells (MNC) were obtained

Journal of Neurorestoratology

138
from each patient by leukapheresis, without any
previous conditioning. Apheresis was performed using
an Optia cell separator (BCT Terumo) using a specific
program to obtain the buffy coat. The MNCs were
processed according to a previous described methodology. MNC were purified by a Ficoll Hypaque
gradient, washed and cultured in DMEM enriched
with 1% bovine skeletal muscle enzymatic hydrolysate
(Laboratorio Villar, Argentina). After 4 days of culture,
as described previously, only lymphocytes pre-sensitized
in vivo against the antigen present in the medium
were activated and amplified by the clonal selection
principle of Burnet [10, 11].
2.2

MSC preparation

Patient’s adipose mesenchymal stromal cells according to identification standard of mesenchymal stromal
cells made by International Society of cell therapy were
obtained from abdominal subcutaneous fat tissue by
minimal liposuction. After special culture, MPC were
differentiated from mesenchymal stem cells which
were mixed in mesenchymal stromal cells [12–14].
The tissue was mechanically and enzymatically
dissociated. The obtained cell suspension was cultivated
in DMEM enriched with recombinant human insulin
and human platelet lysate supernatant. After 3 days of
Table 1
#

1

2

3

4

culture, the cells adhered to the bottom continued to be
cultivated until reaching a semi-confluent state [15].
2.3

MPC preparation

EC and aMSC (from a same patient) were incubated at
a 1:1 ratio. No other substance was added to the culture
medium [15]. For controls, immunohistochemical
staining was performed to detect the phenotypic
expression of PAX 3 (catalog #38-1801, Thermo Fisher),
Myf5 (catalog #PA5-47565), MyoD (catalog #MA1-41017,
Thermo Fisher), Myogenin (catalog #MA1-20978,
Thermo Fisher), Desmin (catalog #MA5-13259, Thermo
Fisher), Vimentin (catalog #MA5-16409), and Actin
(catalog #MA512542, Thermo Fisher) [16, 17]. When
myogenin is expressed, the formation of myotubes
should be observed in the culture [16, 17].
2.4

Patients

Seven chronic complete SCI patients were selected from
a group of patients previously treated with spinal cord
cell therapy and intensive rehabilitation at list for 12
months. All patients are ASIA A in the International
Standards for Neurological Classification of Spinal
Cord Injury. Demographic characteristics of this population are described in Table 1.

Pre-treatment clinical features of the previous SCI treated patients.
Sex

M

M

M

F

Age in
years

23

30

27

18

Time since injury
until treatment

7 years

14 years

3 years

3 years

Injury
level

C5

C6

T4

T 12

ASIA

A

A

A

A

Clinic features

Muscles that recovered electric activity
after spinal cord cell treatment

Spastic quadriplegia

Triceps
Paraspinals
Abdominals (rectus, obliques, transverse)
Gluteus
Quadriceps psoas

Spastic quadriplegia

Triceps
Paraspinals
Abdominals (rectus, obliques, transverse)
Gluteus
Anal Sphincter

Spastic paraplegia

Psoas
Adductors
Quadriceps
Hamstrings
Gluteus

Flaccid paraplegia

Psoas
Adductors
Quadriceps
Hamstrings
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(Continued)

#

5

6

7

Sex

M

F

F

Age in
years

23

53

27

Time since injury
until treatment

6 years

8 years

12 years

Injury
level

T4

T4

T 12

ASIA

A

A

A

Sonogram signs of muscular atrophy were defined
as: changes in the echogenicity (normal hypoechogenic muscular structure replaced by hyperechogenic
image secondary to fibrous and fat tissue infiltration),
changes in volume (smaller thickness and extension
than what was expected for each muscle) [18]
(Fig. 2).
Clinical characteristics of implanted muscles were:
no voluntary movement (0 in Kendal scale), absence of
muscular tone and volume decrease [19]. All implanted
muscles test positive for electrical activity measured
with EMG needle when voluntary desire of contraction [7] (Fig. 2).
Ethics approval to report this case was obtained
from the Ethics Investigation Committee of Universidad
Maimonides (08-10-2015 DI 300-DGDOIN/15).
Written informed consent was obtained from the
patients for their anonymized information to be
published in this article.
2.5

Therapeutic procedure description

Muscles with clinical and sonogram signs of severe
atrophy, but positive electrical activity, were selected
to be implanted [18]. The implant was done by
intramuscular injection under sonogram guidance.

Clinic features

Muscles that recovered electric activity
after spinal cord cell treatment

Flaccid paraplegia

Abdominals (rectus, obliques, transverse)
Paraspinals
Psoas
Quadriceps
Hamstring
Adductors
Tibialis anterior
Triceps sural gluteus

Flaccid paraplegia

Abdominals (rectus, obliques, transverse)
Paraspinals
Psoas
Gluteus.
Anal sphincter

Flaccid paraplegia

Psoas
Adductors
Quadriceps
Hamstrings
Triceps sural
Tibialis anterior
Gluteus
Anal sphincter

The volume and number of cells implanted depended
on the muscle size and are detailed in Table 2 [9].

Fig. 2

Ultrasound and histology, pre and post implant. (A) The

bracket indicates the white muscle band that indicates fibro-adipose
atrophy as is corroborated for the muscle biopsy as is shows in B
picture. (C) Picture indicates the poor but existing neuromuscular
end plates (brown spots) through the Synaptophysin IHC stain.
(D) After the MPC treatment there is able to see the triple muscle
bands detected by sonography: outer black band indicates normal
muscle tissue, as is corroborated by the histology image shows in
Picture E. Middle gray band indicates neo tissue muscle growth
as is corroborated by the histology image of picture F. Picture G
shows that the neuromuscular end plates have increased in number
and extension after the MPC treatment. The inner white muscle band
seen in picture D is not marked by brackets neither a histology
control showed.
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Table 2 Number of cells implanted depending on muscle characteristics
Group

Muscles

Number of cells implanted in each
muscle (EC+MPC)

Small muscles

Deltoid, supraspinous, mayor and minor pectoral,
supinator, finger extensors, hand muscles.

5×106

Medium muscles

Triceps, Biceps, Abdominals (rectus, obliquus),
spinals, adductors, tibialis, gastrocnemius

10×106

Large muscles

Psoas, quadriceps, gluteus, hamstrings

15×106

Intramuscular implants were repeated every 6
weeks and were complemented with intensive rehabilitation. Each muscle received 6–8 implants. Muscular
biopsies were performed before the first implant, after
4 months, and 12 months.
2.6

Evaluation of patient safety and MPC efficacy

Just before the cellular treatment, 24 h after, and 7 days
after the implant, each patient was studied with a
clinical and blood examination that included muscle
enzymes (creatinine phosphokinase and aldolase).
The maximum tolerable level of adverse effects was 2
according to the table of the National Cancer Institute,
USA [17–20], for biological medications elaborated
by NCI for biologic response modifiers (“Common
terminology criteria for adverse events, v3.0”–CTCAE,
http://ctep.cancer.gov/forms/CTCAEv3.pdf).
The efficacy of the treatment was studied through
sonogram [18], muscle biopsy and through the Kendall
clinical scale for muscle contraction [19].
Muscle biopsies were performed with a Pro Mag
Biopsy Needle (catalog #765014120/ARGON Medical
Devices) under sonogram guidance. These biopsies
were studied with regular histological techniques and
immunoblotting techniques with Actin immunoperoxidase (catalog #MA512542, Thermo Fisher), Synaptophysin (catalog #MA514532, Thermo Fisher), MyoD

(catalog #MA141017, Thermo Fisher), Myogenin (catalog
#MA120978, Thermo Fisher), Desmin (catalog
#MA513259, Thermo Fisher), Collagen I (catalog
#sc-59772, Santa Cruz Biotechnology), and Collagen IV
(catalog #MA122148, Thermo Fisher) [16, 17, 21].

3
3.1

Results
Patient’s safety and clinical evolution

All implanted patients tolerated the procedures without
any significant adverse events (Table 3). Post-implant
controls showed no increase in the concentration
of muscle enzymes: creatinine phosphokinase and
aldolase. There were not also variations of other safety
parameters.
Clinical evolution of patients with implanted muscles
and their functional recovery is summarized in Table 4.
Recovery of visible and palpable muscular contraction
were the first clinical signs observed. They were
followed by changes in posture (anti-gravity muscles
improvement) and their ability to perform isolated
movements that were previously absent. There is important to remark that before treatment all implanted
muscles, regardless the electric activity after voluntary
desire of contraction, had no signs of voluntary contraction: 0 in KENDAL scale [19].

Table 3 Frequency of side effects associated to the implant.
Signs/symptoms

N° patients affected

observations

Flu like syndrome

2/7

In all cases they did not last more than 72 h
after the implant

Local events at the implant site: hematoma, edema,
skin symptoms (burning, pain)

6/7

Local hematoma was the most common sign.

Muscular enzyme modification (phosphokinase,
aldolasa) 7 days after implant.

0/7

Blood, lung, heart, kidney function affected

0/7

Measured by clinical and laboratory tests
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Table 4 Implanted muscles and clinical evolution.
Kendall score
#

1

2

Injury
level

C5

C6

Implanted muscles

Before treatment
Right

left

Right

left

Triceps

0/5

0/5

2/5

2/5

Abdominals (rectus,
obliques, transverse)

0/5

0/5

2/5

2/5

Spinals (T1 to L5)

0/5

0/5

2/5

2/5

Gluteus

0/5

0/5

1/5

1/5

Psoas

0/5

0/5

1/5

1/5

Quadriceps

0/5

0/5

1/5

1/5

Triceps

1/5

1/5

3/5

3/5

Abdominals (rectus,
obliques, transverse)

0/5

2/5

2/5

Spinals

0/5

0/5

2/5

2/5

Gluteus

0/5

0/5

0/5

0/5

Psoas

0/5

0/5

0/5

0/5

Anal sphincter

3

4

5

6

T4

T 12

T4

T4

After treatment 18 months
(6 to 8 implants in each muscle)

0/5

0
0/5

0/5

3/5

3/5

Spinals

0/5

0/5

3/5

3/5

Gluteus

0/5

0/5

1/5

1/5

Psoas

0/5

0/5

2/5

2/5

Quadriceps

0/5

0/5

1/5

1/5

Adductors

0/5

0/5

2/5

2/5

Hamstrings

0/5

0/5

1/5

1/5

Gluteus

0/5

0/5

0/5

0/5

Abdominals (rectus,
obliques, transverse)

0/5

0/5

1/5

1/5

Paraspinals

0/5

0/5

1/5

1/5

Psoas

0/5

0/5

1/5

1/5

Quadriceps

0/5

0/5

0/5

0/5

Adductors

0/5

0/5

0/5

0/5

Tibialis anterior

0/5

0/5

0/5

0/5

Triceps sural

0/5

0/5

0/5

0/5

Abdominals (rectus,
obliques, transverse)

0/5

0/5

1/5

1/5

Paraspinals

0/5

0/5

1/5

1/5

Psoas

0/5

0/5

0/5

0/5

Gluteus

0/5

0/5

0/5

0/5

0

Independent standing with
AFO and one support.
Independent walking with
AFO and walker.
Independent seating
without back support.

Independent standing with
AFO and 2 supports.
Independent seating
without back support.

Strong Voluntary contraction

Abdominals (rectus,
obliques, transverse)

Anal sphincter

Functional changes

0

Independent standing with
AFO and walker.
Seating position without
back support.

Independent standing with
AFO and one support.
Independent walking with
AFO and walker.

Independent standing with
AFO and two supports.
Independent walking with
AFO and walker.

Independent standing with
AFO and two supports.
Seating position without
back support.
Active movements of upper
limbs without external
trunk support.
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(Continued)
Kendall score
#

7

Injury
level

T 12

Implanted muscles

Before treatment
Right

left

Right

left

Psoas

0/5

0/5

2/5

2/5

Adductors

0/5

0/5

2/5

2/5

Quadriceps

0/5

0/5

1/5

1/5

Hamstrings

0/5

0/5

2/5

2/5

Triceps sural

0/5

0/5

1/5

1/5

Tibialis anterior

0/5

0/5

0/5

0/5

Gluteus

0/5

0/5

1/5

1/5

Anal sphincter

0

Sonogram evolution: changes were observed in
echogenicity and muscular dimensions. These changes
starting 4 weeks after the first implant. All the implanted
muscles showed clinic and sonogram changes. The
initial homogeneous hyperechogenic image, compatible
with fibro-adipose atrophy, was progressively replaced
by hypoechogenic bands seen as black areas (Fig. 2).
Initially, these areas were located focally in the
implanted spot, however, after the second implant the
black bands were distributed throughout the thickness
and the entire length of the muscle.
3.2

After treatment 18 months
(6 to 8 implants in each muscle)

Patient’s muscle biopsy findings

Biopsied muscles before and 4 months after the
muscular implant were compared by histology and
immunohistochemistry. In a comparative analysis,
pretreatment and post-treatment biopsies were studied,
focusing, for the 4-month control, on the region that
appeared to be regenerating muscle (Figs. 2D middle
band and 2F).
Pre-implant muscle biopsies reveal an important
infiltration of fibro-adipose tissue, surrounding few
and atrophic muscle fibers (Fig. 2B). At high magnification there was able to observe in the muscle
interstitium a reduced number of muscle satellite
cells and the presence of few pro-regenerative cells
(Figs. 3A, 3C, 3E, 3G, 3I, and 3K, orange asterisk
signs) and newly formed fibers (Figs. 3C, 3G, 3I, and
3K, yellow asterisk signs). These new formed muscle
fibers are generally interpreted as failed attempts at
muscle regeneration. These cells and new fibers, as

Functional changes

Independent standing with
AFO and one support.
Independent walking with
AFO and cane.

Poor voluntary contraction

well as the atrophic old fibers, are actin positive
which corroborate the muscle related nature (Fig. 3A).
However, only the newformed muscle fibers and the
interstitium migrating cells are positive for desmin
(Fig. 3C), MyoD (Fig. 3E), and myogenin (Fig. 3G),
which are markers of new/or growing muscle cells.
Synaptophysin HRP stain shows presence of few
neuromuscular end plates on the atrophied muscle
fibers. (Fig. 2C)
The slides done from 4-month treated patients, in the
outer segment of the fine needle muscle biopsy show
young normal muscle tissue (Fig. 2E). The intermedia
area of the same fine needle biopsy (Fig. 2F), shows
an area of active muscle regeneration. Synaptophysin
marks show an increase in the number and size of
the neuromuscular end plates (Fig. 2G). Immunoperoxidase staining for actin (specific to skeletal muscle)
was positive in both biopsies in muscle fiber structures
and cells with presumed pro-regenerative activity
(Fig. 3A and 3B). This result confirms the muscular
nature of the fibers in both biopsies. Desmin reaction
shows that large muscle fibers, minor new formed
muscle fibers and interstitial cells are positive for it
(Fig. 3D, orange, yellow and white asterisk signs,
respectively). Same happens with Myo D and Myogenin
(Figs. 3F and 3H, orange, yellow and white asterisk
signs, respectively). These images assets the assumption
that it is an area of active muscle regeneration.
To explore the relationship between this therapy and
the modification of the atrophic extracellular matrix
(muscle endomysium) it was found that before the
Journal of Neurorestoratology
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Muscular biopsy controls: Actin HRP stain (A) pre-implant, (B) 4-month post-implant; desmin HRP stain (C) pre-implant,

(D) 4-month post-implant; Myo D HRP stain (E) pre-implant, (F) 4-month post-implant; Myogenin HRP stain (G) pre-implant, (H) 4-month
post-implant; collagen Type I HRP stain (I) pre-implant, (J) 4-month post-implant; collagen Type IV HRP Stain (K) pre-implant, (L) 4-month
post-implant. White asterisk signs (*) the large muscle fibers. Yellow asterisk signs (*) new formed muscle fibers. Orange asterisk signs (*)
the interstitial muscular progenitor cells.

treatment collagen type I fibers were in close contact
with the large atrophic muscular fibers and the major
component of the endomysium (Fig. 3I). Opposite,
collagen type IV fibers were only surrounding the
new and frustros muscle fibers (Fig. 3K). The histochemistry study of the fine needle aspiration biopsy of
the treated muscles shows that collagen type I fibers
were almost absent from the muscle endomysium and
collagen type IV fibers were in close relationship with
the growing muscle fibers (Figs. 3J and 3L).

4

Discussion

With the advent of progenitor cell therapy from diverse
origins, regeneration of acute muscle injuries has been
achieved in both the myocardium [22] and skeletal
muscle [23]. However, the results in situations of
chronic muscular atrophy have been partial, when
not failing and limited in duration. Consequently,
chronic muscular atrophy remains one of the unmet
medical needs of modern medicine [24].

This is the first report of isolated clinical cases of
previously chronic complete SCI patients with chronic
muscular atrophy that shows unequivocal signs of
histological, sonogram, and clinical muscular recovery
after receiving MPC therapy.
Although the regimen of neural recovery and muscle
recovery applied to these patients used autologous
aMSC, they were differentiated in the laboratory to
progenitor cells of the tissue to be repaired; furthermore, they were accompanied by tissue-specific EC
for repair. Both the neural lesion and the muscular
atrophy were in the chronic phase. The presence of an
anti-reparative scar in the first case [4] and interstitial
fibrotic degeneration in the second case [3, 21, 23] were
the main obstacles that prevented tissue recovery.
Several authors consider that interstitial fibrosis
is linked to chronic inflammation of tissues. After the
short period of pro-regenerative immune state [5, 6,
25, 26], this process is initiated by the Th2 immune
response and sustained and deepened by Treg. Tregs
are former T helper lymphocytes that, through a
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specific phenotypic modification, became the natural
regulatory cells of Th1 and Th2 reaction [5, 6, 21, 23–27].
They produce, in between other cytokines, large
amount of Transforming Growth Factor b which is
considered the main cause of Fibrotic Scar Induction,
several authors in the fields of oncology and
autoimmunity have demonstrated that the adoptive
administration of Th1 lymphocytes can reverse the
dominance of Th2 and Treg and hence their derived
effects [28].
As shown in Table 1, patients with chronic complete SCI, after local immunomodulation and Neural
Progenitor cell treatment have recovered electrical
activity in muscles innervated for spinal segments
distant between 4 to 12 levels lower than the last one
normally preserved [7, 9]. The more feasible explanation
may be referred that the local immunomodulation
with autologous EC against neural proteins had a key
role to change the scar tissue of the lesion spot for pro
regenerative extracellular matrix. This change in the
extracellular matrix composition allowed the neural
fibers passage through this biological barrier. Moreover,
as we have demonstrated in our previous work, the
simple co-incubation of tissue-specific ECs (activated
in vivo) with aMSC seems to induce the latter to
differentiate into progenitor cells of the tissue corresponding to the specificity of auto-aggressive cells
[15, 29–35]. The changes observed in the extracellular
matrix of the atrophied muscle into pro-regenerative
muscle extracellular matrix (Figs. 2B, 2E and 2F, as
well as Figs. 3I, 3K and 3L) seem also to be directly
related with the local immunomodulation produced
for EC locally implanted [5, 6, 25–27].
At this moment there is an ongoing clinical trial to
confirm these results. They should be confirmed not
only for its importance to satisfy an unmet medical
need, but also because they could be the gateway to
the treatment of various chronic conditions that
constitute several of the more important causes of
disability and dead of our time (chronic heart failure,
chronic brain deterioration, lung fibrosis, etc.) that
are considered non-recoverable.
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